Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.63 |
| ▸ | CCR3 | P51677 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9650868 | 0.94 | HTR2A (0.82) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4211202 | 0.91 | HTR2A (1.00) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9375390 | 0.90 | HTR2A (0.98) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9373922 | 0.90 | HTR2A (0.98) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7839803 | 0.90 | HTR2A (1.00) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL9374754 | 0.89 | HTR2A (0.95) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Oxalic Acid SCHEMBL467239 | 0.89 | HTR2A (0.95) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7828801 | 0.89 | HTR2A (0.97) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7252912 | 0.88 | HTR2A (0.77) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10064464 | 0.85 | KCNH2 (0.81) | HTR2AKDM4ECYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0714292-A4 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | CAMBRIDGE NEUROSCIENCE INC (US) | 1996-10-09 | — | — | EP | claimed |
| EP-0714292-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1996-06-05 | — | — | EP | claimed |
| WO-1995000131-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | CAMBRIDGE NEUROSCIENCE, INCORPORATED (US) | 1995-01-05 | — | — | WO | claimed |
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | UMN PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | UMN PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1879027-A1 | AGENT FOR PREVENTING AND TREATING PANCREATITIS | UMN Pharma Inc. (JP) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | HTR2A, HTR2B, HTR2C | HTR2A 1/4885KDM4E 4086/4885CYP1A2 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.